We provide evidence that reducing the distribution of drugs (e.g diclofenac) with proven CV risk in the heart using nanoparticles will reduce their CV complications without compromising the efficacy.

 

Tags: Bio-Tech, Med-Tech, Health Sciences.

Further Activities to have a look at